Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. Its marketed vaccines include SARS-COV-2 vaccines, HIB conjugate vaccines, 13-valent pneumococcal conjugate vaccines, recombinant hepatitis B vaccines, 23-valent pneumococcal polysaccharide vaccines, diphtheria tetanus acellular pertussis and haemophilus influenzae type b combined vaccines, cell-free whitebait b-type haemophilus influenzae combined vaccines, and measles and rubella combined vaccines. The company's research and development vaccines comprise rabies vaccine for human use, inactivated poliomyelitis vaccine, and live attenuated varicella vaccine. Shenzhen Kangtai Biological Products Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.
| 18.1 | |
| 18.93 | |
| - | |
| 18.93 | |
| 18.08 | |
| 12.93-33.7848 | |
| 20 216 M | |
| 39.3478 | |
| 1 117 M | |
| 3 031 M | |
| 0.1566 | |
| 0.021 | |
| 0.898 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
-- Indicating Technology Transfer of the World's First Dual-carrier 13-valent Pneumococcal Conjugate Vaccine to Indonesia SHENZHEN, China, April 7, 2023 /PRNewswire/ -- On the morning of April 5, Be...
Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market SHENZHEN, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, Beijing Minhai Biotechnology Co., Ltd. h...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
